https://www.biospace.com/bristol-myers-squibb-receives-european-commission-approval-for-opdivo-nivolumab-as-second-line-treatment-for-unresectable-advanced-recurrent-or-metastatic-esophageal-squamous-cell-carcinoma
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Second-Line Treatment for Unresectable Advanced, Recurrent or Metastatic...
bristol myers squibbeuropean commissionreceivesapprovalopdivo
https://www.cancer.gov/news-events/cancer-currents-blog/2025/fda-opdivo-injection?cid=eb_govdel_cancerinfo
FDA has approved Opdivo Qvantig, a form of nivolumab that can be injected under the skin. The original formulation is given as an intravenous infusion.
opdivo qvantigfdanci
https://www.biopharmadive.com/news/bristol-myers-opdivo-fda-approval-neoadjuvant-lung-cancer/619907/
Opdivo's approval is another step in drugmaker efforts to establish immunotherapy drugs earlier in cancer treatment.
first bristolmyerswinsfdaok
https://www.pharmaceutical-technology.com/news/newsbms-receives-european-approval-for-opdivo-to-treat-advanced-melanoma-4606000/
Bristol-Myers Squibb (BMS) has received approval from the European Commission (EC) for its PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), to treat...
bmsreceiveseuropeanapprovalopdivo
https://www.pharmaceutical-technology.com/news/newsbristol-myers-squibbs-opdivo-approved-to-treat-blood-cancer-in-eu-5689641/
Bristol-Myers Squibb's drug Opdivo (nivolumab) has been approved for use in the European Union (EU) to treat classical Hodgkin lymphoma (cHL), a type of blood...
bristol myers squibbblood canceropdivoapprovedtreat